Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026)
Verano Holdings (VRNO) reported Liabilities and Shareholders Equity of $1.7 billion for Q1 2026, down 13.24% year-over-year from $2.0 billion in Q1 2025, and down 1.91% quarter-over-quarter from $1.7 billion in Q4 2025.
Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $1.7 billion in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $1.7 billion, down 13.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (down 14.09% YoY), and the FY2025 annual result was $1.7 billion, down 12.66% from the prior year.
- Liabilities and Shareholders Equity eased to $1.7 billion in Q1 2026 per VRNO's latest filing, from $1.7 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $2.6 billion in Q3 2022 and troughed at $1.7 billion in Q1 2026.
- A 5-year average of $2.2 billion and a median of $2.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity dropped 1.72% in 2024, then dropped 16.82% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.4 billion in 2022, then slipped by 3.23% to $2.3 billion in 2023, then retreated by 14.0% to $2.0 billion in 2024, then slipped by 12.66% to $1.7 billion in 2025, then slipped by 1.91% to $1.7 billion in 2026.
- Business Quant data shows VRNO's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Verano Holdings | - | - | 98.98 Mn | 1.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.71 Bn |
| Dec 31, 2025 | 1.74 Bn |
| Sep 30, 2025 | 1.93 Bn |
| Jun 30, 2025 | 1.94 Bn |
| Mar 31, 2025 | 1.97 Bn |
| Dec 31, 2024 | 1.99 Bn |
| Sep 30, 2024 | 2.31 Bn |
| Jun 30, 2024 | 2.24 Bn |
| Mar 31, 2024 | 2.32 Bn |
| Dec 31, 2023 | 2.32 Bn |
| Sep 30, 2023 | 2.36 Bn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.37 Bn |
| Dec 31, 2022 | 2.40 Bn |
| Sep 30, 2022 | 2.62 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Dec 31, 2021 | 2.55 Bn |